U.S. stocks rose Friday; Humana jumped 12.3% after improved 2027 Medicare Advantage ratings and reaf

TXG teams up with Fred Hutchinson Cancer Center to advance precision oncology through single-cell an

Barclays analyst Luke Sergott maintains 10x Genomics (NASDAQ:TXG) with a Overweight and raises th

10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science

Multi-project collaboration with Fred Hutch Cancer Center spans biomarker discovery in bladder cance

Cathie Wood's ARK dumps $18M of Twist Bioscience while buying Recursion, Veracyte and Intellia,

Torex Gold Resources (TSE: TXG) outlined plans to build on production from its Morelos property in M

Entegris, Rocket and KLA led premarket gains after September payrolls rose just 29,000 vs. 90,000 ex

TXG begins Atera shipments as orders top 40 systems, highlighting strong early demand and broad rese

Leerink Partners analyst Mike Kratky maintains 10x Genomics (NASDAQ:TXG) with a Market Perform an

 Atera is moving into the hands of researchers around the world, from those scaling existing spatial

Sentira Spatial Analysis leverages NVIDIA accelerated computing to cut spatial data processing times

Sentira Spatial Analysis leverages NVIDIA accelerated computing to cut spatial data processing times

Extraordinary early global demand, ambitious new research programs and an expansive technology roadm

Piper Sandler analyst David Westenberg maintains 10x Genomics (NASDAQ:TXG) with a Neutral and rai

Analysts initiate coverage: Buy on IonQ ($60), Jack Henry ($193) and 10X Genomics ($110); Overweight

Argus Research analyst John Eade initiates coverage on 10x Genomics (NASDAQ:TXG) with a Buy ratin

10x Genomics (NASDAQ: TXG - Get Free Report) Director Shehnaaz Suliman sold 5,723 shares of the busi

10x Genomics (NASDAQ: TXG - Get Free Report) CEO Serge Saxonov sold 25,000 shares of 10x Genomics st

Louis says buy the AI dip

Cathie Wood’s ARKG bought Ionis, Beam, Veracyte and Scribe Therapeutics. Here are the biotech ETFs t

On September 21, 2026, 10x Genomics Inc (TXG) shares rose 3.3% to a current price of $79.10. The sto

10x Genomics (NASDAQ: TXG - Get Free Report) and MindWalk (NASDAQ: HYFT - Get Free Report) are both

HB Wealth Management LLC purchased a new stake in 10x Genomics (NASDAQ: TXG) in the undefined quarte

U.S. stocks fell, but Radiant Logistics surged 17.8% after beating Q4 estimates. Waystar, Telix and

Lunit (KRX: 328130), a leading provider of AI for cancer diagnostics and precision oncology, today a

10x Genomics, a leader in single-cell and spatial biology, to combine its spatial biology technologi

UBS analyst Dan Leonard maintains 10x Genomics (NASDAQ:TXG) with a Neutral and raises the price t

On September 08, 2026, 10x Genomics Inc (TXG) shares rose 4.7% today, bringing the current price to

TXG's 84% rally is backed by consumables growth, Atera demand and higher guidance, but weak instrume

The biotech sector has a new catalyst beyond GLP-1 drugs. Moderna Inc (NASDAQ:MRNA) and Merck & Co I

Moderna’s cancer vaccine breakthrough puts biotech, mRNA and genomics ETFs in focus. Here are the fu

RBC Capital analyst Dan Leonard initiates coverage on 10x Genomics (NASDAQ:TXG) with a Sector Per

10x Genomics wins a $4.8M patent verdict against Parse, strengthening its IP position as it seeks ad

10x Genomics won a $4.8 million patent infringement lawsuit against Qiagen subsidiary Parse Bioscien

10x Genomics Wins Patent Infringement Verdict Against Parse Biosciences PR Newswire PLEASANTON, Cali

Jury finds Parse willfully infringed Scale Biosciences' patents and rejects Parse's invalidi

Jury finds Parse willfully infringed Scale Biosciences' patents and rejects Parse's invalidity chall

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

Atera could meaningfully boost instrument sales in late 2026 and drive recurring high-margin consuma

Dow Jones up 200 points on Wed. Estee Lauder & other top stocks record gains after reporting str

Stephens & Co. analyst Mason Carrico maintains 10x Genomics (NASDAQ:TXG) with a Overweight an

Piper Sandler analyst David Westenberg maintains 10x Genomics (NASDAQ:TXG) with a Neutral and rai

Canaccord Genuity analyst Kyle Mikson maintains 10x Genomics (NASDAQ:TXG) with a Buy and raises t

Citigroup analyst Brendan Digan maintains 10x Genomics (NASDAQ:TXG) with a Neutral and raises the

Morgan Stanley analyst Tejas Savant maintains 10x Genomics (NASDAQ:TXG) with a Equal-Weight and r

10x Genomics (NASDAQ:TXG) raises FY2026 sales outlook from $600.000 million-$625.000 million to $610

10x Genomics (NASDAQ:TXG) reported quarterly losses of $(0.14) per share which beat the analyst cons

This collaboration builds on 10x's broader efforts to work with leading research institutions to

Tema's new Healthcare AI ETF (HLTH), targets AI-powered drug discovery, diagnostics, robotics an